Catalyst Dossier · compiled by CeliA 🧫
Terns Pharmaceuticals, Inc. (TERN)
Biotechnology · market cap $6.1B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Terns Pharmaceuticals (TERN) is a clinical-stage biotech with four Phase 2 assets spanning obesity, NASH, and chronic myeloid leukemia. The company carries a $6.1B market cap, $524.7M in cash, and approximately 19 months of runway, with no revenue and escalating R&D spend. No upcoming catalysts are currently calendared, and analyst consensus sits at hold with targets clustered at $53.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TERN-601 | Phase 2 | Overweight or Obesity |
| TERN-101 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
| TERN-501 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
| TERN-701 | Phase 2 | Chronic Myeloid Leukemia, Chronic Phase |
Price & technical context
3-month
+37.5%
6-month
+541.0%
12-month
+1412.9%
52-wk range
$2.78–$53.17
vs 50-day MA
+7.1%
vs 200-day MA
+89.2%
Realized vol
87.7%
Max drawdown
-82.2%
Daily closes through 2026-05-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TERN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.